PROTAC

Jun 08, 2026

Summary HR+/HER2- breast cancer continues to represent a major target indication for SERDs, with approximately 481,000 cases reported in 2024 in the 7MM.  High-profile failures from Sanofi (amcenestrant) and a long list of early-stage candidates such as GDC-029, AZD9496, GDC-0927, ZnC5, LSZ-102, brinale...

Jan 10, 2025

Molecular glues are a groundbreaking class of small molecules that are gaining significant attention in the field of drug discovery. These compounds offer a novel approach to modulating protein function, especially for challenging targets that have been difficult to address using traditional drug discovery methods....